Literature DB >> 33328302

Membrane-associated and secreted forms of the Rhesus macaque rhadinovirus-encoded CD200 homologue and cellular CD200 demonstrate differential effects on Rhesus Macaque CD200 Receptor signaling and regulation of myeloid cell activation.

Ryan D Estep1, Aparna N Govindan2, Kristin Fitzpatrick2, Tiffany C Blair2, S A Rahim Rezaee3, David J Blackbourn4, Scott W Wong1,5,6.   

Abstract

The CD200-CD200R pathway is involved in inhibition of immune responses, and the importance of this pathway to infectious disease is highlighted by the fact that viral CD200 (vCD200) molecules have been found to be encoded by several DNA viruses, including the human gammaherpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV), and the closely related rhesus macaque rhadinovirus (RRV). KSHV vCD200 is the most extensively studied vCD200 molecule, however, the only herpesvirus vCD200 molecule to be examined in vivo is that encoded by RRV. Our prior studies have demonstrated that RRV vCD200 is a functional CD200 homologue that is capable of affecting immune responses in vivo, and further, that RRV can express a secreted form of vCD200 (vCD200-Sec) during infection. Despite this information, RRV vCD200 has not been examined specifically for effects on RM CD200R signaling, and the functionality of vCD200-Sec has not been examined in any context. Thus, we developed an in vitro model system in which B cells expressing vCD200 were utilized to assess the effects of this molecule on the regulation of myeloid cells expressing RM CD200R, mimicking interactions that are predicted to occur in vivo Our findings suggest that RRV vCD200 can bind and induce functional signals through RM CD200R, while vCD200-Sec represents a non-functional protein incapable of affecting CD200R signaling. We also provide the first demonstration of the function of RM CD200, which appears to possess more robust signaling capabilities than RRV vCD200, and also show that KSHV vCD200 does not efficiently induce signaling via RM CD200R.IMPORTANCE Viral CD200 homologues are encoded by KSHV and the closely related RRV. Though RRV vCD200 has been examined, questions still exist in regard to the ability of this molecule to induce signaling via rhesus macaque CD200R, as well as the potential function of a secreted form of vCD200. Further, all previous in vitro studies of RRV vCD200 have utilized an Fc fusion protein to examine functionality, which does not replicate the structural properties of the membrane-associated form of vCD200 that is naturally produced during RRV infection. In this study, we demonstrate for the first time that membrane-expressed RRV vCD200 is capable of inducing signal transduction via RM CD200R, while the secreted form of vCD200 appears to be non-functional. Further, we also demonstrate that RM CD200 induces signaling via RM CD200R, and is more robust than RRV vCD200, while KSHV vCD200 does not appear to induce efficient signaling via RM CD200R.
Copyright © 2020 American Society for Microbiology.

Entities:  

Year:  2020        PMID: 33328302      PMCID: PMC8092840          DOI: 10.1128/JVI.01654-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Human herpesvirus 8 K14 protein mimics CD200 in down-regulating macrophage activation through CD200 receptor.

Authors:  Mildred Foster-Cuevas; Gavin J Wright; Michael J Puklavec; Marion H Brown; A Neil Barclay
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

2.  Molecular mechanisms of CD200 inhibition of mast cell activation.

Authors:  Shuli Zhang; Holly Cherwinski; Jonathon D Sedgwick; Joseph H Phillips
Journal:  J Immunol       Date:  2004-12-01       Impact factor: 5.422

3.  Ectodomain shedding of CD200 from the B-CLL cell surface is regulated by ADAM28 expression.

Authors:  Tal Twito; Zhiqi Chen; Ismat Khatri; Karrie Wong; David Spaner; Reg Gorczynski
Journal:  Leuk Res       Date:  2013-05-01       Impact factor: 3.156

4.  Down-regulation of basophil function by human CD200 and human herpesvirus-8 CD200.

Authors:  Ikuo Shiratori; Masao Yamaguchi; Maho Suzukawa; Kazuhiko Yamamoto; Lewis L Lanier; Takashi Saito; Hisashi Arase
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

5.  Identification of tyrosine residues crucial for CD200R-mediated inhibition of mast cell activation.

Authors:  Shuli Zhang; Joseph H Phillips
Journal:  J Leukoc Biol       Date:  2005-12-05       Impact factor: 4.962

6.  Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function.

Authors:  G J Wright; M J Puklavec; A C Willis; R M Hoek; J D Sedgwick; M H Brown; A N Barclay
Journal:  Immunity       Date:  2000-08       Impact factor: 31.745

7.  High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease.

Authors:  Eric Oksenhendler; Emmanuelle Boulanger; Lionel Galicier; Ming-Qing Du; Nicolas Dupin; Tim C Diss; Rifat Hamoudi; Marie-Thérèse Daniel; Félix Agbalika; Chris Boshoff; Jean-Pierre Clauvel; Peter G Isaacson; Véronique Meignin
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

8.  Characterization of the CD200 receptor family in mice and humans and their interactions with CD200.

Authors:  Gavin J Wright; Holly Cherwinski; Mildred Foster-Cuevas; Gary Brooke; Michael J Puklavec; Mike Bigler; Yaoli Song; Maria Jenmalm; Dan Gorman; Terri McClanahan; Man-Ru Liu; Marion H Brown; Jonathon D Sedgwick; Joseph H Phillips; A Neil Barclay
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

Review 9.  The CD200-CD200R1 inhibitory signaling pathway: immune regulation and host-pathogen interactions.

Authors:  Christine A Vaine; Roy J Soberman
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

10.  Structures of CD200/CD200 receptor family and implications for topology, regulation, and evolution.

Authors:  Deborah Hatherley; Susan M Lea; Steven Johnson; A Neil Barclay
Journal:  Structure       Date:  2013-04-18       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.